Related Experiment Videos
[Pharmacological biomodulation in cancer]
1Laboratorio de Cultivo de Tejidos y Biología de Tumores, Instituto de Biología Experimental, Facultad de Ciencias, Universidad Central de Venezuela, Apartado Postal 47114, Caracas, 1041-A Venezuela.
Acta Cientifica Venezolana
|August 21, 2001
Summary
P-glycoprotein (Pgp) mediates multidrug resistance (MDR) in cancer. Agents reversing this resistance are being investigated in clinical studies worldwide for improved cancer treatment outcomes.
Area of Science:
- Pharmacology
- Oncology
- Molecular Biology
Background:
- P-glycoprotein (Pgp) is a key mediator of multidrug resistance (MDR) in cancer.
- Pgp is present in various human epithelial tissues and malignancies, both untreated and pretreated with chemotherapy.
- The identification of agents that can reverse Pgp-mediated resistance in vitro has spurred significant research interest.
Purpose of the Study:
- To review recent advancements in the experimental and clinical investigation of multidrug resistance reversing agents in cancer therapy.
- To highlight the significance of P-glycoprotein in antineoplastic pharmacology.
Main Methods:
- Review of experimental studies on MDR reversing agents.
- Analysis of clinical investigations involving MDR reversing agents.
- Examination of P-glycoprotein's role in drug resistance.
Main Results:
- P-glycoprotein's discovery is a major breakthrough in cancer pharmacology.
- Demonstration of Pgp in human malignancies and its role in resistance.
- Identification of agents capable of reversing in vitro resistance.
Conclusions:
- Multidrug resistance reversing agents show promise for cancer treatment.
- Further clinical studies are warranted to evaluate the efficacy of these agents.
- Understanding Pgp's role is crucial for overcoming chemotherapy resistance.